S-甲基谷胱甘肽 | 2922-56-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: S-甲基谷胱甘肽
• 英文名称: (S)-2-Amino-4-[(R)-1-(carboxymethyl-carbamoyl)-2-methylsulfanyl-ethylcarbamoyl]-butyric acid
• 英文别名: S-Methyl glutathione；N-[(4S)-4-azaniumyl-4-carboxylatobutanoyl]-S-methyl-L-cysteinylglycine；(2S)-2-azaniumyl-5-[[(2R)-1-(carboxymethylamino)-3-methylsulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoate
• CAS: 2922-56-7
• 化学式: C₁₁H₁₉N₃O₆S
• mdl: MFCD00056730
• 分子量: 321.354
• InChiKey: QTQDDTSVRVWHMO-BQBZGAKWSA-N

物化性质

• 沸点：
  765.1±60.0 °C(Predicted)
• 密度：
  1.399±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4.1
• 重原子数：
  21
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.636
• 拓扑面积：
  184
• 氢给体数：
  5
• 氢受体数：
  8

ADMET

代谢

甲基谷胱甘肽是1-碘甲烷的人体代谢物。

Methylglutathione is a known human metabolite of 1-iodomethane.

来源:NORMAN Suspect List Exchange

安全信息

• 海关编码：
  2930909090
• WGK Germany：
  3

制备方法与用途

生物活性

S-甲基谷胱甘肽（S-Methylglutathione，GS-Me）是一种S取代的谷胱甘肽，比GSH更具亲核性。S-甲基谷胱甘肽对乙二醛酶1 (glyoxalase 1) 具有抑制作用。

体外研究

S-甲基谷胱甘肽是一种比谷胱甘肽（GSH）更强的亲核试剂，这一特性可以解释为甲基团的正诱导效应更为显著。

反应信息

• 作为反应物：
  描述：

  S-甲基谷胱甘肽 生成 γ-L-glutamyl-S-methyl-L-cysteine
  参考文献：
  名称：

  Zacharius et al., Archives of Biochemistry, 1959, vol. 80, p. 199,204

  摘要：

  DOI：
• 作为产物：
  描述：

  谷胱甘肽 、 碘甲烷 在 sodium hydroxide 、 氮气 作用下， 以 乙醇 、 水 为溶剂， 生成 S-甲基谷胱甘肽
  参考文献：
  名称：

  LOW-FAT FOOD

  摘要：

  一种低脂肪食品，含有能够激活钙受体的氨基酸或肽，例如γ-Glu-X-Gly、γ-Glu-Val-Y、γ-Glu-Ala、γ-Glu-Gly、γ-Glu-Cys、γ-Glu-Met、γ-Glu-Thr、γ-Glu-Val、γ-Glu-Orn、Asp-Gly、Cys-Gly、Cys-Met、Glu-Cys、Gly-Cys、Leu-Asp、D-Cys、γ-Glu-Met(O)、γ-Glu-γ-Glu-Val、γ-Glu-Val-NH2、γ-Glu-Val-ol、γ-Glu-Ser、γ-Glu-Tau、γ-Glu-Cys(S-Me)(O)、γ-Glu-Leu、γ-Glu-Ile、γ-Glu-t-Leu、γ-Glu-Cys(S-Me)等，其中X和Y是氨基酸或氨基酸衍生物。

  公开号：

  US20100120698A1

文献信息

• Substitution reactions of [Pt(dien)Cl]+, [Pt(dien)(GSMe)]2+, cis-[PtCl2(NH3)2] and cis-[Pt(NH3)2(GSMe)2]2+ (GSMe =S-methylglutathione) with some sulfur-bonding chemoprotective agents
  作者：Kelemu Lemma、Sofi K. C. Elmroth、Lars I. Elding

  DOI：10.1039/b110138m

  日期：——

  using stopped-flow and conventional UV/VIS spectrophotometry. The reactions of 1 with 2-mercaptoethanesulfonate (mesna) and 2-mercaptoethylamine (cysteamine), which is the parent compound of 2-(3-aminopropylamino)ethylphosphorothioic acid (WR2721), and of cis-[Pt(NH3)2(GSMe)2]2+ with thiosulfate have also been studied. The reactions between cisplatin and DDTC, thiourea and thiosulfate were investigated

  含硫化合物用作救援剂，以保护正常组织免受顺式-[PtCl 2（NH 3）2 ]（顺铂）的毒副作用，而不会影响其抗肿瘤活性。模型配合物[Pt（dien）Cl] +（1）和[Pt（dien）（GSMe）] 2+（2）（GSMe = S-甲基谷胱甘肽）与救援剂谷胱甘肽（GSH），硫脲，硫代硫酸盐的反应，和二乙基二硫代氨基甲酸酯（DDTC）已在1.0 mol dm -3高氯酸盐水溶液介质中，37°C和pH 7.30下使用流阻和常规UV / VIS分光光度法进行了研究。1的反应用2-巯基乙（美司钠）和2-巯基乙胺（半胱胺），其是2-（3-氨基丙基氨基）ethylphosphorothioic酸（WR2721）的母体化合物，以及顺式- [PT（NH 3）2（GSME）2 ] 还研究了含硫代硫酸盐的2+。在37°C的无缓冲0.10–0.05 mol dm -3氯化物介质中研究了顺铂与DDTC，硫脲和硫代
• Kokumi-imparting agent
  申请人：Ohsu Takeaki

  公开号：US09395376B2

  公开（公告）日：2016-07-19

  The present invention encompasses a method for screening for a kokumi-imparting substance by using the calcium receptor activity as an index, a composition containing a kokumi-imparting substance obtained by the screening method, a method for producing food or drink imparted with kokumi, and food or drink imparted with kokumi.

  本发明涵盖了一种利用钙受体活性作为指标筛选口感增强物质的方法，一种通过筛选方法获得口感增强物质的组合物，一种制备口感增强食品或饮料的方法，以及口感增强的食品或饮料。
• METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS
  申请人：XenoPort, Inc.

  公开号：US20150038499A1

  公开（公告）日：2015-02-05

  Methods of improving patient safety and reducing undesirable side effects for patients considering therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed. In particular, a method of treating a disease in a patient in need of such treatment is provided. The method comprises testing the patient for a propensity for a deficiency in tissue glutathione S-transferase theta 1 enzyme (GSTT1) levels. Thereafter, a therapeutically effective amount of a compound selected from monomethyl fumarate (MMF), a prodrug of monomethyl fumarate, and combinations thereof is administered to the patient. During the treatment of the disease, blood lymphocyte concentration is periodically tested in the patient at a predetermined time interval length that is based on the enzyme level propensity testing result.

  本发明涉及改善患者安全和减少治疗使用单甲基富马酸及其前药所产生的不良副作用的方法。具体而言，本发明提供了一种治疗患者疾病的方法。该方法包括对患者进行组织谷胱甘肽S-转移酶θ1酶（GSTT1）水平缺陷的倾向性测试。随后，向患者施用单甲基富马酸（MMF）、单甲基富马酸前药或其组合的治疗有效量。在治疗疾病期间，以基于酶水平倾向性测试结果的预定时间间隔长度定期检测患者的血淋巴细胞浓度。
• LOW-FAT FOOD
  申请人：Nagasaki Hiroaki

  公开号：US20100120698A1

  公开（公告）日：2010-05-13

  A low-fat food containing an amino acid or a peptide which is able to activate a calcium receptor, examples of which include γ-Glu-X-Gly, γ-Glu-Val-Y, γ-Glu-Ala, γ-Glu-Gly, γ-Glu-Cys, γ-Glu-Met, γ-Glu-Thr, γ-Glu-Val, γ-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, γ-Glu-Met(O), γ-Glu-γ-Glu-Val, γ-Glu-Val-NH 2 , γ-Glu-Val-ol, γ-Glu-Ser, γ-Glu-Tau, γ-Glu-Cys(S-Me)(O), γ-Glu-Leu, γ-Glu-Ile, γ-Glu-t-Leu, γ-Glu-Cys(S-Me), etc, wherein X and Y are an amino acid or an amino acid derivative.

  一种低脂肪食品，含有能够激活钙受体的氨基酸或肽，例如γ-Glu-X-Gly、γ-Glu-Val-Y、γ-Glu-Ala、γ-Glu-Gly、γ-Glu-Cys、γ-Glu-Met、γ-Glu-Thr、γ-Glu-Val、γ-Glu-Orn、Asp-Gly、Cys-Gly、Cys-Met、Glu-Cys、Gly-Cys、Leu-Asp、D-Cys、γ-Glu-Met(O)、γ-Glu-γ-Glu-Val、γ-Glu-Val-NH2、γ-Glu-Val-ol、γ-Glu-Ser、γ-Glu-Tau、γ-Glu-Cys(S-Me)(O)、γ-Glu-Leu、γ-Glu-Ile、γ-Glu-t-Leu、γ-Glu-Cys(S-Me)等，其中X和Y是氨基酸或氨基酸衍生物。
• Platinum(II) complexes containing dicyclopentadiene and dithiocarbamate as anticancer agents
  申请人：King Fahd University of Petroleum and Minerals

  公开号：US11117912B1

  公开（公告）日：2021-09-14

  A family of platinum(II) complex with mixed ligands as anticancer agents. The platinum(II) ion is coordinated to dicyclopentadiene and dithiocarbamate ligands. Also described are a pharmaceutical composition incorporating the platinum(II) complex, a methods of synthesizing the platinum(II) complex, and a method of treating cancer. The platinum(II) complexes exhibit potent cytotoxicity against lung and cervical cancer cell lines as well as low nephrotoxicity.

  一种以混合配体为抗癌剂的铂(II)配合物家族。铂(II)离子与二环戊二烯和二硫代氨基甲酸盐配体配位。还描述了包含铂(II)配合物的制药组合物、制备铂(II)配合物的方法以及治疗癌症的方法。铂(II)配合物对肺癌和宫颈癌细胞系表现出强烈的细胞毒性，同时肾毒性较低。